Register for free
Recent Quotes
My Watchlist
Indicators
Business Insurance Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Crispr Therapeutics Ag (NQ: CRSP )

51.17 +0.33 (+0.65%)
Streaming Delayed Price Updated: 1:00 PM EST, Nov 29, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Crispr Therapeutics Ag

< Previous 1 2
...
6 7 8 9 10 11 12 13 14
...
30 31 Next >
Could CRISPR Therapeutics Become the Next Vertex Pharmaceuticals?
It's not as long a shot as some might think. 
Via The Motley Fool
Looking for Growth? 2 Top Stocks to Buy Hand Over Fist
These stocks offer enormous long-term growth potential. 
Via The Motley Fool
3 Biotech Stocks That Could Be Multibaggers in the Making
Uncover investment opportunities with biotech stocks representing firms developing critical breakthroughs in treatments. 
Via InvestorPlace
Cathie Wood's ARK Innovation ETF Achieves 35% Gain In November, Its Best Month Since Inception
The ARK Innovation ETF (NYSE:ARKK), managed by renowned investor Cathie Wood, has posted remarkable gains in November, making it the fund’s best-performing month since its launch in 2014. 
Via Benzinga
Topics ETFs
Jim Cramer: Buy Shares Of This Personal Computer Giant, Wait For 'A Little Bit Of Pullback'
On CNBC’s "Mad Money Lightning Round," Jim Cramer said he would not buy CRISPR Therapeutics AG (NASDAQ: CRSP) stock "all the way up here. 
Via Benzinga
Is CRISPR Therapeutics the Best Gene-Editing Stock?
The biotech's first-mover advantage bodes well for its long-term prospects. 
Via The Motley Fool
3 Top-Rated Biotech Stocks That Analysts Are Loving Now
Investing in biotech stocks can be tricky, but analysts have bullish outlooks on these three, promising companies. 
Via InvestorPlace
2 Dirt-Cheap Stocks That Could Rocket Higher in a Bull Market
These stocks may take off in a market favoring growth. 
Via The Motley Fool
Investing in These 3 Stocks Now Could Make You a Millionaire Retiree
These innovators should have tremendous long-term growth prospects. 
Via The Motley Fool
3 Biotech Stocks That Could Be Millionaire Makers
Many biotech stocks offer exciting long-term growth prospects. 
Via The Motley Fool
Are You A Trader Or Investor: Biotech Momentum Is Picking Up
ETFs have not helped as portfolio fillers but they can identify trends. We should play this rally out of a biotech bear market. 
Via Talk Markets
Topics ETFs
What's Going On With Crispr Therapeutics Stock Monday?
CRISPR Therapeutics AG (NASDAQ: CRSP) shares are trading higher Monday on what appears to be continued momentum from the recent regulatory authorization of the company's  
Via Benzinga
Google’s Bard AI Says These 3 Stocks Will Rise 1,000%
Google's Bard has been among the best stock pickers, and thinks these three stocks have quadruple-digit upside potential. 
Via InvestorPlace
Topics Artificial Intelligence
Exposures Artificial Intelligence
2 Beaten-Down Growth Stocks That Could Rocket 42% to 67% Higher, According to Wall Street
Investment bank analysts are pounding the table on these stocks, but are they right for your portfolio? 
Via The Motley Fool
Could Investing $10,000 In CRISPR Therapeutics Stock Make You a Millionaire?
The stock is trading below its peak, reached a couple of years ago. 
Via The Motley Fool
3 Monster Stocks in the Making
These stocks could grow much larger over the next few years. 
Via The Motley Fool
Why CRISPR Therapeutics Stock Is Jumping Again Today
The stock continues to enjoy momentum from a key regulatory approval. 
Via The Motley Fool
Ross Stores Reports Strong Earnings, Joins Buckle, Twist Bioscience And Other Big Stocks Moving Higher On Friday
U.S. stocks traded mostly lower, with the Dow Jones falling over 20 points on Friday. 
Via Benzinga
Topics Stocks
Exposures US Equities
CRISPR Therapeutics Stock Earns 88 RS Rating On U.K. Regulator News
CRISPR Therapeutics sees its Relative Strength Rating enter the 80-plus level. 
Via Investor's Business Daily
3 Long-Term Growth Stocks Analysts Are Bullish On
Here are three long-term growth stocks for your consideration if you’re looking to take a long position in a new name or two. 
Via InvestorPlace
3 Cathie Wood You’ll Regret Not Buying Soon: November 2023
Cathie Wood thinks we're out of the woods economically, and these stock picks in her portfolio stand to gain the most in coming months. 
Via InvestorPlace
Why Is NIO Stock Down 5% Today?
Nio stock is falling on Thursday as investors react to negative news following the summit between Presidents Xi Jinping and Joe Biden. 
Via InvestorPlace
Crispr Surges After Winning The First-Ever Approval For A CRISPR-Based Gene-Editing Drug
The drug will sell under the brand name Casgevy in the UK for two blood diseases. 
Via Investor's Business Daily
What's Going On With Crispr Therapeutics Stock Thursday?
CRISPR Therapeutics AG (NASDAQ: CRSP) shares are trading higher Thursday after the company announced regulatory authorization of the first CRISPR/Cas9 gene- 
Via Benzinga
Citi Is Souring on Plug Power (PLUG) Stock
Plug Power stock is falling on Thursday after the EV charging company's shares were hit with a downgrade and lowered price target from Citi. 
Via InvestorPlace
CRISPR Therapeutics (CRSP) Stock Jumps as U.K. Authorizes Gene Therapy
CRSP stock is up on U.K. authorization for its gene therapy treatment for sickle cell anemia. CRISPR hopes for FDA authorization next spring. 
Via InvestorPlace
Exposures Product Safety
UK Approves First Crispr Gene Edited Therapy For Sickle Cell Disease, Beta Thalassemia
The U.K. 
Via Benzinga
Why Palo Alto Networks Shares Are Trading Lower By Around 5%; Here Are 20 Stocks Moving Premarket
Shares of Palo Alto Networks, Inc. (NASDAQ: PANW) fell in pre-market trading after reporting first-quarter results. 
Via Benzinga
Can CRISPR Therapeutics Stock Double in 5 Years? Here's What It Would Take.
A few things put together could push the stock higher. 
Via The Motley Fool
Vertex and CRISPR Therapeutics Announce Authorization of the First CRISPR/Cas9 Gene-Edited Therapy, CASGEVY™ (exagamglogene autotemcel), by the United Kingdom MHRA for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia
From Vertex Pharmaceuticals Incorporated
Via Business Wire
< Previous 1 2
...
6 7 8 9 10 11 12 13 14
...
30 31 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

Business Insurance is a singular, authoritative news and information source for executives focused upon risk management, risk transfer and risk financing.

Never miss important news. Subscribe to our newsletter.
Register for free

Information

Copyright 2024. BUSINESS INSURANCE HOLDINGS